FDA Dampens Outlook With Another Ophthalmic Bevacizumab CRL

Cites ‘Only One Deficiency – Lack Of Substantial Evidence Of Effectiveness’

 
• By Dave Wallace
  
Outlook was “very disappointed” by the FDA’s decision (Shutterstock)

More from Value Added Medicines

More from Products